drugset / Trial / NCT01594437

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

NCT01594437 ↗

Phase 1 Completed 48 enrolled Theraclone Sciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety profile in healthy adult volunteers of single or multiple intravenous administrations of TCN-202 as compared with placebo.

Timeline

Start
2012-05
Primary completion
2012-12
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject TCN-202 Monoclonal antibody — Intravenous